10-Q quarterly report · filed Nov 10, 2026

Tyra Biosciences, Inc. (TYRA) Q3 2026 10-Q Quarterly Report

Short answer

Tyra Biosciences, Inc. (TYRA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$51M
−71.2% YoY · −12.2% QoQ
EPS (diluted)
−$0.74
−48.0% YoY · −7.2% QoQ

Source: XBRL data from the Tyra Biosciences, Inc. (TYRA) Q3 2026 10-Q on SEC EDGAR. USD.

Tyra Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, clinical-stage company with no product revenue
  • Net loss $51.1M vs $29.9M YoY, operating margin not applicable with operating expenses $54.9M
  • Dabogratinib IR NMIBC largest R&D program, $7.3M vs $1.8M YoY; TYRA-200 ICC lowest, $(0.1)M vs $0.0M
  • Cash, equivalents and marketable securities $700.5M at September 30, 2026, financing proceeds $376.2M
  • Runway through 2030; expected higher R&D spending, clinical-trial costs and operating losses, with tariffs and geopolitical risks as headwinds

Risk Factors

  • No material changes to risk factors disclosed in the 2025 Annual Report
  • Carried-forward risks include clinical-trial, regulatory approval, commercialization, and financing uncertainties
  • Continued biotechnology competition and dependence on intellectual-property protection
  • Ongoing need for additional capital to support operations and development programs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Tyra Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.